Bristol Laboratories: UK Public Sector Contracts Won & Awards

Companies House: Private Limited CompanyBerkhamstedNationwide (UK)Main market: Pharmaceutical products

Companies House03393503 ↗ · Active

Where they win
i

19 awards (19 for a named lot, 100%, 0 for a whole procedure with no lot named) · top CPV classes, shares of all 19 awards. An award may cover more than one class.

3360 Pharmaceutical products18 awards · 95% · awards naming a lot
3369 Various medicinal products1 award · 5% · awards naming a lot
Attributable award value
i
£249kOn 2 of 19 award records; the five largest make 100%. Largest rows below.

Where their buyers are
i

ITL1 region of the buyer office · known for 19 of 19 awarded procedures · each procedure counts once

Greater London7 procedures · 37%
North West England4 procedures · 21%
South East England3 procedures · 16%
Scotland3 procedures · 16%
Wales (Cymru)2 procedures · 11%

Who they sell to
i

Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier

Authority type · official UK type when published, else name/id class, else not classified · by award records (a single panel can dominate)
i
  • NHS & health100%(19 awards)
    19 of 19 awards are NHS & health (100%).
AuthorityProceduresShareAward recordsLast activity
NHS Englandframework/DPS on 2736.8%84 Mar 2024
The NHS Commissioning Board (operating under the name of NHS England)framework/DPS on 4421.1%1130 Nov 2021
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")framework/DPS on 3315.8%37 Apr 2025
ATAMIS LTD315.8%37 Jul 2023
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)210.5%21 Feb 2024

Share = of the 19 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.

Contracts ending
i

20 of 27 awards carry an end date, 7 estimated from the duration · not a retender forecast

ContractEndsPublished value
Generic Drugs - Tablets & Capsules31 Jan 2027£25,385
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)31 May 2027Not published
Wave 14c - Orals (plus non-parenteral) Products (all regions)31 May 2027£1 ceiling
All Other Cardiovascular & Respiratory Medicines21 Mar 2028 estimated£24,410,075 ceiling

Recent awards

Latest 19 of 19 award records naming this supplier

Other official notice feeds add 8 more procedures won by this supplier. Each is counted once beside any Find a Tender copy; they are in the totals, not in this list.

Award / procedureAuthorityAwardedPublished value
NHS National Pharmaceuticals - Everolimus and terminated agreement productsThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
NHS National Pharmaceuticals - Everolimus and terminated agreement productsThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
Transition Products - LSNE RegionThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
Transition Products - NWLN RegionThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
Transition Products - CESW RegionThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
Hospital Only/Housekeeping - DLN/DCE/DSW RegionsThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
Oral (plus non-parenteral) Products - All RegionsThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
Hospital Only/Housekeeping - DLS/DNE/DNW RegionsThe NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
NHS National Generic Pharmaceuticals Interim 2 2020The NHS Commissioning Board (operating under the name of NHS England)Not published£1 †
framework ceiling · not attributable revenue
About this data
  • One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
  • Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
  • Regions in the buyer chart describe the buyer office, not where the work is delivered or the supplier’s registered address.
  • Contract end dates. Published on 13 of 27 awards, estimated from the published duration on 7 more (marked “estimated”); those feed “Contracts ending”. Published values in that list come from either source; Contracts Finder figures are shown as published and stay out of this profile’s money totals.
  • Source. Official UK public procurement notices (Find a Tender, Contracts Finder and Public Contracts Scotland), reused under the Open Government Licence v3.0, updated through the day and rebuilt nightly. Not every figure uses every feed, and each one shows how many records it rests on: see the methodology. Spotted something wrong? Tell us.